Faculty of Medicine
GRIN Disorders Research Fund
GRIN Disorders are rare genetic conditions that affect a protein in the body known as the N-methyl-D-aspartate (NMDA) receptor, which is crucial for normal brain development and for learning and memory. They include a range of symptoms including severe epilepsy, physical disabilities, and cognitive impairments. Many people with the disease are unable to walk, talk, and feed themselves. But there is hope. Researchers at the University of Toronto are working with colleagues around the world to identify therapies and cures for thousands of people worldwide living with GRIN Disorders, caused by variants in the GRIN1, GRIN2A, GRIN2B and GRIN2D genes.
This fund supports GRIN Disorder research at the University of Toronto, in partnership with the CureGRIN Foundation (CureGRIN.org), including funding for animal models, research into biomarkers, and the discovery and development of pharmacological and gene therapy treatments. 100% of funds are designated to research.
CureGRIN was founded and run by parents committed to finding cures and therapies for people living with GRIN Disorders.